Your fact-checks will appear here
The efficacy of abemaciclib in the treatment of HR+/HER2- advanced breast cancer, including its real-world effectiveness and toxicity profile.
Three orally administered CDK4/6 inhibitors—, and —are widely accepted first‑line partners to endocrine therapy in and have broadly similar efficacy for progression‑free survival in trials, though rea...
Three —, and —sit firmly as the standard first-line systemic option for HR‑positive, HER2‑negative advanced/metastatic breast cancer when combined with endocrine therapy, with guideline bodies and ran...
, as tested in the program, is the only CDK4/6 inhibitor with consistent, statistically significant overall survival (OS) advantages reported across multiple phase III trials (MONALEESA‑2, ‑3, and ‑7)...